Sponsor
Air Force Military Medical University, China
Clinical research sponsor
How to interpret these research links
Connected source recordsThe exact organization name Air Force Military Medical University, China appears in 26 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
26 shownCoil-Assisted Small-Diameter Covered-Stent Shunt Reduction for Refractory Hepatic Encephalopathy After TIPSNCT07799948 · lead sponsor · 2026-09-01
RECRUITINGTIPS for Platinum-Related Porto-Sinusoidal Vascular Disease With Variceal BleedingNCT06635122 · lead sponsor · 2024-07-01
UNKNOWNProspective Screening and Differentiating Common Cancers Using Peripheral Blood Cell-Free DNA SequencingNCT06036563 · lead sponsor · 2023-09-01
UNKNOWNHVPG-Guided Therapy vs Carvedilol Plus Endotherapy for the Prevention of Esophageal Variceal Rebleeding in Cirrhotic PatientsNCT04254822 · lead sponsor · 2020-06-01
UNKNOWNApplication of Diffusion Weighted MRI Versus CT in Evaluation of the Effect of Treating Lung CancerNCT02320617 · lead sponsor · 2014-12-01
UNKNOWNStudy of Bosentan in the Treatment of Stable Severe Chronic Obstructive Pulmonary Disease PatientsNCT02093195 · lead sponsor · 2013-12-01
UNKNOWNEpidemiological Study of Chronic Thromboembolic Pulmonary Hypertension in ChinaNCT01717092 · lead sponsor · 2012-10-01
UNKNOWNStudy of the Initial Combination of Bosentan With Iloprost in the Treatment of Pulmonary Hypertension PatientsNCT01712997 · lead sponsor · 2012-09-01
UNKNOWNTIPS With 8- OR 10-mm Covered Stent for Preventing Variceal RebleedingNCT01410591 · lead sponsor · 2012-07-01
COMPLETEDThe Effectiveness of L-ornithine-L-aspartate (LOLA) on Plasma Ammonia in Cirrhotic Patients After TIPSNCT01440829 · lead sponsor · 2011-12-01
COMPLETEDImpact of Benfluorex Versus Metformin on Glucose Control and Insulin Secretion in Chinese Type 2 Diabetic PatientsNCT00544518 · lead sponsor · 2007-10-01
UNKNOWNPlasma Exosomal RNA Signature for Prostate Cancer Bone MetastasisNCT07553754 · collaborator · 2026-03-12
RECRUITINGA Multicenter, Prospective Study on the Prognostic Value of PSMA PET in Patients With Newly Diagnosed, Treatment-naïve Prostate CancerNCT07474142 · collaborator · 2026-03-03
RECRUITINGPlasma exoRNA-Based Liquid Biopsy to Diagnose Clinically Significant Prostate CancerNCT07492927 · collaborator · 2021-03-12
RECRUITINGSerial PSMA PET for Therapy Monitoring in Clinically Significant Prostate CancerNCT07553780 · collaborator · 2021-03-07
RECRUITINGDelayed PSMA PET/CT Imaging for Diagnosing Clinically Significant Prostate Cancer in Biopsy-Naïve Men With Suspected Prostate CancerNCT07531329 · collaborator · 2021-03-05
RECRUITINGLorlatinib as Neoadjuvant Treatment in Stage IB-IIIB ALK-rearranged Non-Small Cell Lung CancerNCT06682884 · collaborator · 2024-11-15
NOT_YET_RECRUITINGStudy of the Effects of Transcutaneous Vagus Nerve Stimulation on Cancer PatientsNCT04563013 · collaborator · 2020-09-23
COMPLETEDPostmastecomy Internal Mammary Nodal Irradiation for High-risk Breast Cancer PatientsNCT04320979 · collaborator · 2020-05-08
ACTIVE_NOT_RECRUITINGA Study of Individualized Diagnosis and Treatment for Major Depressive Disorder With Atypical FeaturesNCT04209166 · collaborator · 2019-08-12
UNKNOWNElectromagnetic Navigation Versus CT Guided TTNA in the Diagnosis of Early Peripheral Lung CancerNCT03802266 · collaborator · 2019-01-01
UNKNOWNOptimizing and Individualizing the Pharmacological Treatment of First-episode Schizophrenic PatientsNCT03451734 · collaborator · 2018-01-23
COMPLETEDMulti-Dimensional Diagnosis,Individualized Therapy,and Management Technique for Major Depressive Disorder:Based on Clinical and Pathological CharacteristicsNCT03219008 · collaborator · 2017-08-01
UNKNOWNComparison of Exenatide vs. Biphasic Insulin Aspart 30 on Glucose Variability in Type 2 DiabetesNCT02449603 · collaborator · 2015-11-01
COMPLETEDCancer and Anesthesia: Survival After Radical Surgery - a Comparison Between Propofol or Sevoflurane AnesthesiaNCT01975064 · collaborator · 2013-11-01
COMPLETEDEfficacy and Safety of Firebird 2 Stent in Treatment of Complex Coronary Lesions in DiabetesNCT01257373 · collaborator · 2010-04-01
UNKNOWNDrugs studied in this sponsor's trials
10 mapped RxNorm conceptsThese drug records are connected through ClinicalTrials.gov studies listing Air Force Military Medical University, China as a sponsor, collaborator or responsible party. Each count is the number of distinct trials containing the mapped drug intervention. This does not establish that the organization manufactures, owns, sells or developed the drug.
bosentan2
carvedilol1
exenatide1
fluoxetine1
fluvoxamine1
iloprost1
lorlatinib 100 MG1
metformin1
bosentan RxCUI 75207 · Lead sponsor in 2 linked trial(s) · 0 currently recruiting
2 trials
carvedilol RxCUI 20352 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting
1 trial
exenatide RxCUI 60548 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting
1 trial
fluoxetine RxCUI 4493 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting
1 trial
fluvoxamine RxCUI 42355 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting
1 trial
iloprost RxCUI 40138 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting
1 trial
lorlatinib 100 MG RxCUI 2103176 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting
1 trial
metformin RxCUI 6809 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting
1 trial
propofol RxCUI 8782 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting
1 trial
sevoflurane RxCUI 36453 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting
1 trial
Sponsor roles
collaborator15
lead sponsor11
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.